When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
Shares of allogenic CAR T cell therapy concern Allogene have lost more than 45% of their value since peaking at $55 post-readout of its ALLO-501 candidate.
A slightly dilutive secondary and tepid initial results from its BCMA-targeting therapy ALLO-715 are to blame.
With significant competition and no shortage of clinical and preclinical assets in a very in-vogue space, Allogene merited a deeper dive.
A full investment analysis is presented in the paragraphs below.